8 HOW THE GROWING DEMAND FOR GLP-1s IS IMPACTING THE MARKETPLACE & CREATING A COMPOUNDING CRAZE Recent polling finds that about one in eight adults (12%) report having taken a GLP-1 agonist.11 The huge demand for these drugs is leading to medication shortages, inconsistent insurance coverage, and dubious counterfeits or compounded versions that create challenges for companies and consumers
However, it is currently classified in Group B of the AIS, which means that benefits are possible but the evidence remains insufficient or contradictory
Stress is considered a silent killer, but more specifically, it is oxidative stress in our cells thats linked to disease, decline, and health issues
Doing it wrong can cause bruising, bleeding, or even infection
Wadley AJ, Svendsen IS, Gleeson M
46 KrainzT.GaschlerM